Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLS-005 in Spinocerebellar Ataxia
NCT05490563Phase 3Terminated
- Sponsor
- Seelos Therapeutics, Inc.
- Start
- Jun 2022
- Primary completion
- Nov 2023
- Modality
- Drug Delivery Systems, DNA Intercalators/Alkylators, Metabolically Activated Prodrugs
- Countries
- 8
01
Overview
A Phase 3 trial of trehalose in spinocerebellar ataxia type 3 (SCA3), sponsored by Seelos Therapeutics, Inc.. Started Jun 2022; status: terminated.
02
Drugs
trehalose
03
Conditions
spinocerebellar ataxia type 3 (SCA3)
Beyond the preview
Go deeper on NCT05490563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05490563.